While OS did not improve significantly across patient cohorts treated with CAR T cell therapy, a single patient who did not receive post-CAR glioblastoma treatment remained alive 59 months after EGFRvIII-CAR T cell therapy.431 Furthermore, some patients treated with HER2-CAR T cell therapy maintained a stable condition for up to 29 months.433 A patient receiving anti-IL13Rα2 CAR T cells demonstrated a complete response (determined by clinical and radiographic observations) for 7.5 months,434 suggesting promising potential for this immunotherapy in glioblastoma treatment. The gene discussed is ERBB2; the disease is glioblastoma.